Cue Biopharma, Inc.
CUE
$30.44
$1.364.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.47M | 7.10M | 8.29M | 7.99M | 9.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.47M | 7.10M | 8.29M | 7.99M | 9.29M |
| Cost of Revenue | 35.64M | 26.10M | 30.42M | 32.04M | 33.69M |
| Gross Profit | -8.18M | -19.00M | -22.14M | -24.05M | -24.41M |
| SG&A Expenses | 18.34M | 19.11M | 17.34M | 17.17M | 17.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.99M | 45.21M | 47.76M | 49.21M | 50.88M |
| Operating Income | -26.52M | -38.11M | -39.48M | -41.22M | -41.59M |
| Income Before Tax | -26.10M | -37.68M | -38.90M | -40.58M | -40.67M |
| Income Tax Expenses | 500.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.60 | -37.68 | -38.90 | -40.58 | -40.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.60M | -37.68M | -38.90M | -40.58M | -40.67M |
| EBIT | -26.52M | -38.11M | -39.48M | -41.22M | -41.59M |
| EBITDA | -25.56M | -37.73M | -39.08M | -40.82M | -41.20M |
| EPS Basic | -9.39 | -13.67 | -16.53 | -19.94 | -22.48 |
| Normalized Basic EPS | -5.78 | -8.53 | -10.36 | -12.50 | -14.08 |
| EPS Diluted | -9.40 | -13.67 | -16.53 | -19.94 | -22.48 |
| Normalized Diluted EPS | -5.79 | -8.53 | -10.36 | -12.50 | -14.08 |
| Average Basic Shares Outstanding | 12.62M | 11.49M | 9.84M | 8.33M | 7.50M |
| Average Diluted Shares Outstanding | 12.70M | 11.49M | 9.84M | 8.33M | 7.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |